-
Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis.
Nat MedNoti M, Wojno ED, Kim BS, Siracusa MC, Giacomin PR, Nair MG, Benitez AJ, Ruymann KR, Muir AB, Hill DA, Chikwava KR, Moghaddam AE, Sattentau QJ, Alex A, Zhou C, Yearley JH, Menard-Katcher P, Kubo M, Obata-Ninomiya K, Karasuyama H, Comeau MR, Brown-Whitehorn T, de Waal Malefyt R, Sleiman PM, Hakonarson H, Cianferoni A, Falk GW, Wang ML, Spergel JM, Artis D -
An enzyme that inactivates the inflammatory mediator leukotriene b4 restricts mycobacterial infection
PLoS OneTobin DM, Roca FJ, Ray JP, Ko DC, Ramakrishnan L -
TLR-2/TLR-4 TREM-1 signaling pathway is dispensable in inflammatory myeloid cells during sterile kidney injury.
PLoS OneCampanholle G, Mittelsteadt K, Nakagawa S, Kobayashi A, Lin SL, Gharib SA, Heinecke JW, Hamerman JA, Altemeier WA, Duffield JS -
Omalizumab for chronic urticaria
N Engl J MedAltman MC, Naimi DR -
Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12.
ImmunityShafiani S, Dinh C, Ertelt JM, Moguche AO, Siddiqui I, Smigiel KS, Sharma P, Campbell DJ, Way SS, Urdahl KB -
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
LancetMoran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group., Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group. -
A SNP in G6PC2 predicts insulin secretion in type 1 diabetes.
Acta DiabetolSanda S, Wei S, Rue T, Shilling H, Greenbaum CJ -
Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.
Clin Exp ImmunolBollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ -
Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073.
DiabetesGreenbaum CJ, Beam CA, Type 1 Diabetes TrialNet Study Group. -
Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA).
Ann Rheum DisHughes-Austin JM, Deane KD, Derber LA, Kolfenbach JR, Zerbe GO, Sokolove J, Lahey LJ, Weisman MH, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM -
Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08:01 and DRB1*11:01 Is predicted by their structural motifs and correlates with disease risk.
J ImmunolChow IT, James EA, Gates TJ, Tan V, Moustakas AK, Papadopoulos GK, Kwok WW -
Cutting edge: the pathogenicity of IFN-γ-producing Th17 cells is independent of T-bet.
J ImmunolDuhen R, Glatigny S, Arbelaez CA, Blair TC, Oukka M, Bettelli E -
Cutting edge: allergen-specific CD4 T cells respond indirectly to thymic stromal lymphopoietin to promote allergic responses in the skin.
J ImmunolLarson RP, Comeau MR, Ziegler SF -
Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28.
J ImmunolHuang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF -
Immunological biomarkers: catalysts for translational advances in autoimmune diabetes.
Clin Exp ImmunolAhmed ST, Akirav E, Bradshaw E, Buckner JH, McKinney E, Quintana FJ, Waldron-Lynch F, Nepom GT
